LOS ANGELES, Jan. 17, 2018 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today
highlighted that aldoxorubicin licensee NantCell, Inc., a
private subsidiary of NantWorks, LLC, has dosed the first patient
in the Phase 1b portion of a Phase
1b/2 clinical trial for patients with
metastatic pancreatic cancer. The trial will investigate
high-affinity natural killer (haNK) cell therapy in combination
with anti-cancer agents, including aldoxorubicin, in metastatic
pancreatic cancer patients who have progressed on or following
standard-of-care therapy.
"NantCell's decision to include aldoxorubicin in this new trial
speaks to their commitment to expanding its potential use in
combination with immuno-oncology agents and cell-based therapies,"
said Steven A. Kriegsman, CytRx's
Chairman and CEO.
The trial titled "QUILT-3.070: Molecularly Informed
Integrated Immunotherapy Combining Innate High-affinity Natural
Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines
to Induce T-cell Responses in Subjects With Pancreatic Cancer Who
Have Progressed on or After Standard-of-care Therapy,"
(NCT03387098) is a single-center, open-label, Phase 1b/2 clinical trial designed to evaluate the
safety and efficacy of several combination therapies, including
combinations with aldoxorubicin, in subjects with pancreatic cancer
who have progressed on or after previous standard of care
chemotherapy. This trial is expected to enroll approximately
173 patients. The primary endpoint for the Phase 1b portion of the trial is safety and the primary
endpoint for the Phase 2 portion of the trial is objective response
rate (ORR) by RECIST.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical company specializing in
research and clinical development of novel anti-cancer drug
candidates that employ linker technologies to enhance the
accumulation and release of drug at the tumor. CytRx is also
rapidly expanding its pipeline of ultra-high potency oncology
candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated
Drug Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker technology
for the development of a new class of potential breakthrough
anti-cancer therapies. Aldoxorubicin, CytRx's most advanced
drug conjugate, is an improved version of the widely used
anti-cancer drug doxorubicin and has been out-licensed to NantCell,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to plans for regaining compliance with the
Nasdaq rules and higher share price of our common stock; the
ability of NantCell, Inc., to obtain regulatory approval for its
products that use aldoxorubicin; the ability of NantCell, Inc., to
manufacture and commercialize products or therapies that use
aldoxorubicin; the amount, if any, of future milestone and royalty
payments that we may receive from NantCell, Inc.; our ability to
develop new ultra-high potency drug candidates based on our
LADR™ technology platform; and other risks and
uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and Exchange Commission
and current reports filed since the date of CytRx's most recent
annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-highlights-dosing-of-the-first-patient-in-licensee-nantcell-inc-clinical-trial-investigating-cell-based-therapy-in-combination-with-multiple-anti-cancer-agents-including-aldoxorubicin-in-patients-with-metastat-300583726.html
SOURCE CytRx Corporation